Document is current
Any future updates will be listed below
-
Authors
Latif, Kareem
Nishida, Takashi https://orcid.org/0000-0002-8312-6623
Moghimi, Sasan
Weinreb, Robert N.
-
Funding
Funding for this research was provided by:
National Eye Institute (R01EY029058)
National Eye Institute (P30EY022589)
National Eye Institute (R01EY034148)
Research to Prevent Blindness (an unrestricted grant)
- License Information
-
More Information
Article History
Received: 3 December 2022
Revised: 7 March 2023
Accepted: 24 March 2023
First Online: 5 April 2023
Declarations
:
: This article does not contain any studies with human participants or animals performed by any of the authors.
: Takashi Nishida and Sasan Moghimi are the consultants of Topcon. Robert Weinreb received grants from National Eye Institute, Bausch & Lomb, and received research instrument from Heidelberg Engineering, Topcon, Carl Zeiss Meditec, Optovue, and Centervue. He has the license of Carl Zeiss Meditec; patent of Toromedes; and stocks of Equonox, Eyenovia, Iantrek, Implandata, and IOPtic. He also is a consultant of Aerie Pharmaceuticals, Alcon, Allergan, Amydis, Equinox, Eyenovia, Iantrek, Implandata, IOPtic, Nicox, and Topcon; is an advisory board of Iantrek, Impandata, Amydid, and Eyenovia; and is a chief editor of International Glaucoma Review. No other disclosures were reported.
